Business · 1 sources covering this

Multiple growth triggers ahead for Aurobindo Pharma as outlook stays strong

Respiratory launches, CDMO expansion and strong US and European businesses are key growth drivers; the stock trades at just under 16 times estimated FY28 earnings

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

Business StandardCenter·3h ago
Multiple growth triggers ahead for Aurobindo Pharma as outlook stays strong
Respiratory launches, CDMO expansion and strong US and European businesses are key growth drivers; the stock trades at just under 16 times estimated FY28 earnings
Read at Business Standard →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/d543d60b0d71544288a4bd74d49a7b5819adac5f"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Multiple growth triggers ahead for Aurobindo Pharma as outlook stays strong"></iframe>

Multiple growth triggers ahead for Aurobindo Pharma as outlook stays strong

How 1 sources are covering this

Multiple growth triggers ahead for Aurobindo Pharma as outlook stays strong

More from Business

India among just two regions where incomes rising, says WEF survey

SC reserves verdict on states' power to impose additional tax, surcharge

Milk prices might stay elevated during upcoming flush season, say experts

India on track to add about 8 GW wind energy capacity in FY27: MNRE

Reader

Trust & legal

Across the network